• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 8:27:09 AM ET
    $AMAG
    Major Pharmaceuticals
    Health Care
    Get the next $AMAG alert in real time by email
    SC 13G/A 1 camberamag-202013ga.htm PRIMARY DOCUMENT camberamag-202013ga
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No 1)
     
    AMAG Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
    00163U106
    (CUSIP Number)
     
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
    Persons who respond to the collection of information contained in this form are not
    required to respond unless the form displays a currently valid OMB control number.
     
    13G
    CUSIP No. 00163U106
    Page 2 of 6
     
                                                 
    1. Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    0  shares
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Camber Capital Management LP – 0 shares
        10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Camber Capital Management LP – 0%
    12. Type of Reporting Person
    Camber Capital Management LP – 00 (Limited Partnership)
     
    13G
    CUSIP No.   00163U106
    Page 3 of 6

    1. Names of Reporting Persons.
    Stephen DuBois
    Not applicable
     
    2. Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
        3. SEC Use Only
    4. Citizenship or Place of Organization
    Stephen DuBois – United States
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
    5. Sole Voting Power
    0 shares
    6. Shared Voting Power
    0  shares
    7. Sole Dispositive Power
    0 shares
    8. Shared Dispositive Power
    0  shares
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    Stephen DuBois – 0 shares
       10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares       ☐
    11. Percent of Class Represented by Amount in Row (9)
    Stephen DuBois – 0%
    12. Type of Reporting Person
    Stephen DuBois – IN
     
    13G
      CUSIP No.     00163U106
    Page 4 of 6
     
    The Reporting Persons initially reported their beneficial ownership of the Issuer on a Schedule 13G filed with the Securities and Exchange Commission (the "Commission") on July 31, 2017 and subsequently reported their beneficial ownership on a Schedule 13D filed with the Commission on September 20, 2019 (the "Schedule 13D"). Pursuant to Rule 13d-1(h), the Reporting Persons are eligible to again report their beneficial ownership of shares of Common Stock of the Issuer on a Schedule 13G, and this Schedule 13G shall operate as an amendment to the Schedule 13D.
     
    ITEM 1.
                  (a) Name of Issuer
    AMAG Pharmaceuticals Inc.
     
    (b) Address of Issuer's Principal Executive Offices:
    1100 Winter Street Waltham, MA 02451
     
    ITEM 2.
    (a) Name of Person Filing:
    Camber Capital Management LP
    Stephen DuBois
     
    (b) Address of Principal Business Office, or if None, Residence:
    Camber Capital Management LP
    Stephen DuBois
    101 Huntington Avenue
    Suite 2101
    Boston, MA 02199
     
    (c) Citizenship:
    Camber Capital Management LP – Delaware
    Stephen DuBois – United States
     
    (d) Title of Class of Securities:
    Common Stock, par value $0.01 per share
     
    (e) CUSIP Number:
    00163U106
     
     
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
     
     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Act  (15 U.S.C. 78o).
     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).   
     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).   
     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    [_]
    An investment adviser in accordance with  ss.240.13d-1(b)(1)(ii)(E);   
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);   
     
    (g)
    [_]
    A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);   
     
    (h)
    [_]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);   
     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);   
     
    (j)
    [_]
    Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
     
    ITEM 4. OWNERSHIP.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a) Amount beneficially owned: Camber Capital Management LP –  0 shares
    Stephen DuBois – 0 shares
     
    (b) Percent of class: Camber Capital Management LP – 0% 
    Stephen DuBois – 0%
     
     
    13G
       CUSIP No.     00163U106
    Page 5 of 6
     
    (c) Number of shares as to which such person has:
     
    (i) Sole power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (ii) Shared power to vote or to direct the vote
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iii) Sole power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
    (iv) Shared power to dispose or to direct the disposition of
    Camber Capital Management LP – 0 shares
    Stephen DuBois – 0 shares
     
     
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ x].
     
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    Not applicable
     
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
    Not applicable
     
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
     
    Not applicable
     
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     
    Not applicable
     
     
    13G
    CUSIP No.     00163U106 
    Page 6 of 6
     
     
     
    ITEM 10. CERTIFICATIONS.
    The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c):
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    CAMBER CAPITAL MANAGEMENT LP
    By: /s/Sean George
    Sean George
    Chief Financial Officer
     
    STEPHEN DUBOIS
    By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
     
    Get the next $AMAG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Landsdowne Labs Names Bryan Laulicht CEO

      Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

      6/13/23 9:05:00 AM ET
      $MGTX
      $AMAG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Pharmaceuticals
    • Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h

      12/20/21 1:30:00 AM ET
      $DVAX
      $HARP
      $AMAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

      WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors

      2/9/21 7:30:00 AM ET
      $FRLN
      $AQST
      $AMAG
      $SCYX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals

    $AMAG
    Leadership Updates

    Live Leadership Updates

    See more
    • Landsdowne Labs Names Bryan Laulicht CEO

      Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

      6/13/23 9:05:00 AM ET
      $MGTX
      $AMAG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Pharmaceuticals
    • Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (PARIS:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director. Scott, who also serves as Chairman of the Board at Dynavax Technologies (NASDAQ:DVAX) and Harpoon Therapeutics (NASDAQ:HARP), brings almost 30 years of global experience in the pharmaceutical and medical technology industries to Sensorion. Previously, Mr Myers served as the Chief Executive Officer and Director of AMAG Pharmaceuticals, Inc (NASDAQ:AMAG), where h

      12/20/21 1:30:00 AM ET
      $DVAX
      $HARP
      $AMAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

      WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors

      2/9/21 7:30:00 AM ET
      $FRLN
      $AQST
      $AMAG
      $SCYX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals

    $AMAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

      2/16/21 4:24:39 PM ET
      $AMAG
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

      2/16/21 8:27:09 AM ET
      $AMAG
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AMAG PHARMACEUTICALS, INC. (0000792977) (Subject)

      2/10/21 3:19:44 PM ET
      $AMAG
      Major Pharmaceuticals
      Health Care